Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 167

1.

Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overview.

De Ponti F, Poluzzi E, Cavalli A, Recanatini M, Montanaro N.

Drug Saf. 2002;25(4):263-86. Review.

PMID:
11994029
2.

QT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience.

De Ponti F, Poluzzi E, Montanaro N.

Eur J Clin Pharmacol. 2000 Apr;56(1):1-18. Review.

PMID:
10853872
3.

Organising evidence on QT prolongation and occurrence of Torsades de Pointes with non-antiarrhythmic drugs: a call for consensus.

De Ponti F, Poluzzi E, Montanaro N.

Eur J Clin Pharmacol. 2001 Jun;57(3):185-209. Review.

PMID:
11497335
4.
5.

QT prolongation with antimicrobial agents: understanding the significance.

Owens RC Jr.

Drugs. 2004;64(10):1091-124. Review.

PMID:
15139788
6.

The QT interval and torsade de pointes.

Moss AJ.

Drug Saf. 1999;21 Suppl 1:5-10; discussion 81-7. Review.

PMID:
10597863
7.

[Drug induced QT prolongation].

Altmann D, Eggmann U, Ammann P.

Wien Klin Wochenschr. 2008;120(5-6):128-35. doi: 10.1007/s00508-008-0940-6. Review. German.

PMID:
18365152
8.

QT prolongation through hERG K(+) channel blockade: current knowledge and strategies for the early prediction during drug development.

Recanatini M, Poluzzi E, Masetti M, Cavalli A, De Ponti F.

Med Res Rev. 2005 Mar;25(2):133-66. Review.

PMID:
15389727
9.
10.

Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development.

Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S, Siegl PK, Strang I, Sullivan AT, Wallis R, Camm AJ, Hammond TG.

Cardiovasc Res. 2003 Apr 1;58(1):32-45. Review.

PMID:
12667944
11.

Antipsychotic-related QTc prolongation, torsade de pointes and sudden death.

Haddad PM, Anderson IM.

Drugs. 2002;62(11):1649-71. Review.

PMID:
12109926
12.

Torsade de pointes due to noncardiac drugs: most patients have easily identifiable risk factors.

Zeltser D, Justo D, Halkin A, Prokhorov V, Heller K, Viskin S.

Medicine (Baltimore). 2003 Jul;82(4):282-90. Review.

13.

[QTc-prolonging drugs and the risk of sudden death].

Reingardiene D, Vilcinskaite J.

Medicina (Kaunas). 2007;43(4):347-53. Review. Lithuanian.

14.

Torsadogenic cardiotoxicity of antipsychotic drugs: a structural feature, potentially involved in the interaction with cardiac HERG potassium channels.

Testai L, Bianucci AM, Massarelli I, Breschi MC, Martinotti E, Calderone V.

Curr Med Chem. 2004 Oct;11(20):2691-706. Review.

PMID:
15544470
15.

Drugs that cause Torsades de pointes and increase the risk of sudden cardiac death.

Wolbrette DL.

Curr Cardiol Rep. 2004 Sep;6(5):379-84. Review.

PMID:
15306095
16.

[Lengthening of QT interval by antipsychotic drugs].

Haverkamp W, Deuschle M.

Nervenarzt. 2006 Mar;77(3):276, 278-80, 282-4 passim. Review. German.

PMID:
16052325
17.

[Antipsychotic drugs and cardiovascular safety: current studies of prolonged QT interval and risk of ventricular arrhythmia].

Gury C, Canceil O, Iaria P.

Encephale. 2000 Nov-Dec;26(6):62-72. Review. French.

PMID:
11217540
18.

Long QT syndrome caused by noncardiac drugs.

Viskin S, Justo D, Halkin A, Zeltser D.

Prog Cardiovasc Dis. 2003 Mar-Apr;45(5):415-27. Review.

PMID:
12704598
20.

Drug-induced long QT syndrome and torsade de pointes.

Morissette P, Hreiche R, Turgeon J.

Can J Cardiol. 2005 Aug;21(10):857-64. Review.

PMID:
16107909

Supplemental Content

Support Center